A recent study suggests that patients who come off popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle programs.
Findings released in a major health publication points out that while obese people can lose about a fifth of their body weight while on the medication, the weight comes back at an estimated rate of nearly a kilo each month upon discontinuation.
"People using such drugs must be informed of the risk of rapid rebound weight gain when the treatment ends," warns expert Dr. Susan Jebb.
This pace of regain implies a reversion to starting weight within about a year and a half.
Comparing Approaches
The analysis, which reviewed 37 of trials involving thousands of patients, compared the outcomes of GLP-1 agonists with older methods.
The team note that individuals who shed pounds through diet and exercise typically see a slower creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Doctors suggest the mode of action of the injections is key to understanding the heightened weight return.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of the hormone levels far above than the body's typical production may cause the system to produce less of its endogenous hormone, and could reduce responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this medication leads to appetite is uncontrolled, making overeating far more likely."
A Lifelong Issue?
Health authorities recommend the jabs for individuals with weight-linked health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, considering the high risk of relapse, the therapy should be considered life-long.
This view is reinforced by pharmaceutical companies, who say that the results "emphasize the chronic character of excess weight," akin to managing conditions like diabetes.
User Experiences
People who have discontinued the jabs describe a intense resurgence of hunger.
"It felt as if something that goes on and I was suddenly extremely hungry," described a patient.
This difficulty is worsened if patients have not established permanent dietary or behavioural modifications during therapy.
Widespread Interest
Recent estimates suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Use is higher among females than men.
- The middle-aged age group shows the highest level of interest.
- Many obtain the drugs through private healthcare rather than public health services.
In conclusion, clinicians caution that while these medications are potent agents for weight loss, they are not a standalone cure and lasting health benefits hinges on combined lifestyle management.
